Clinical Trial NU UCSF12I01
- Phase II Trial of the Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma (124511)
- Principal Investigator
- Halla Nimeiri
- Status: CLOSED
- Study Type: Therapeutic
- Protocol No:.NU UCSF12I01
- The purpose of this study is to find out what effects (good and/or bad)the drug combination of Temsirolimus and Sorafenib has on advanced hepatocellular carcinoma (HCC).
- HCC is a liver cancer that cannot be removed by surgery. Sorafenib is the standard treatment for HCC. Sorafenib works by turning off some of the chemicals in the tumor cells that let the tumor grow new blood vessels. Temsirolimus works by turning off some of the chemicals that help cells grow and divide. An earlier study (Phase 1) shows promise that the addition of Temsirolimus will make Sorafenib more effective in the treatment of HCC. Temsirolimus is approved by Food & Drug Administration (FDA) for treatment of kidney cancer but it's use in treating HCC is considered experimental.
Some of the eligibility criteria include:
- Participants must be 18 years of age or older
- Participants must have advanced inoperable hepatocellular carcinoma.
- Participants may not have had prior chemotherapy for their HCC.
- Description of Treatment
- Participants will take both Sorafenib and Temsirolimus for a 28 day cycle. Particpants will be assessed for results after each cycle. Treatment will continue for participants until their disease worsens, they experience unacceptable side effects, or the study doctor decides it is in their best interest to be removed from the study.
- Sara Duffey
Clinical Research and Education Specialist
Robert H. Lurie Comprehensive Cancer Center
Find Related Clinical Trials
Browse by Disease Sites
Other Clinical Trials by Halla Nimeiri
- A Randomized, Double-blind, Placebo-controlled Phase 2 Study of MM-141 plus Nab-paclitaxel and Gemcitabine versus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer
- A Phase I/II Study of the Combination of Temozolomide and Pazopanib in Advanced Pancreatic Neuroendocrine Tumors (PNET)
last updated: 03-Dec-16 01:38 PM
Clinical trial availability changes frequently. Please check this site often for updates or call 312.695.1102 for personal assistance.